CN115611855B - 烟碱酰胺型化合物及其在制备减肥药物中的应用 - Google Patents
烟碱酰胺型化合物及其在制备减肥药物中的应用 Download PDFInfo
- Publication number
- CN115611855B CN115611855B CN202210513052.3A CN202210513052A CN115611855B CN 115611855 B CN115611855 B CN 115611855B CN 202210513052 A CN202210513052 A CN 202210513052A CN 115611855 B CN115611855 B CN 115611855B
- Authority
- CN
- China
- Prior art keywords
- mmol
- compound
- nmr
- cdcl
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 8
- -1 Nicotinamide compound Chemical class 0.000 title abstract description 22
- 229960003966 nicotinamide Drugs 0.000 title abstract description 8
- 235000005152 nicotinamide Nutrition 0.000 title abstract description 8
- 239000011570 nicotinamide Substances 0.000 title abstract description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 150000005480 nicotinamides Chemical class 0.000 claims abstract description 9
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 24
- 229960002715 nicotine Drugs 0.000 abstract description 24
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 17
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 108090001060 Lipase Proteins 0.000 abstract description 3
- 239000004367 Lipase Substances 0.000 abstract description 3
- 102000004882 Lipase Human genes 0.000 abstract description 3
- 235000019421 lipase Nutrition 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 150000002190 fatty acyls Chemical group 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 170
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 238000012512 characterization method Methods 0.000 description 30
- 239000012141 concentrate Substances 0.000 description 30
- 239000003480 eluent Substances 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 27
- 239000007787 solid Substances 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 22
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 238000010791 quenching Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 229930182840 (S)-nicotine Natural products 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- SNICXCGAKADSCV-SNVBAGLBSA-N (+)-nicotine Chemical compound CN1CCC[C@@H]1C1=CC=CN=C1 SNICXCGAKADSCV-SNVBAGLBSA-N 0.000 description 3
- 229930182841 (R)-nicotine Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical compound OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QRHUZEVERIHEPT-UHFFFAOYSA-N 2,6-difluorobenzoyl chloride Chemical compound FC1=CC=CC(F)=C1C(Cl)=O QRHUZEVERIHEPT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GGHLXLVPNZMBQR-UHFFFAOYSA-N 3,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC(Cl)=C1 GGHLXLVPNZMBQR-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- AVTLLLZVYYPGFX-UHFFFAOYSA-N 4-ethylbenzoyl chloride Chemical compound CCC1=CC=C(C(Cl)=O)C=C1 AVTLLLZVYYPGFX-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- VMJXPEQQNSGRNX-UHFFFAOYSA-N OS(=O)(=O)C(C)=C(N)CO Chemical compound OS(=O)(=O)C(C)=C(N)CO VMJXPEQQNSGRNX-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001161 sympathoadrenergic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一类烟碱酰胺型化合物及其在制备减肥药物中的应用，该化合物的结构式为或或或
Description
技术领域
本发明属于化学药物技术领域，具体涉及一类烟碱酰胺型化合物及其在制备减肥药物中的应用。
背景技术
烟碱(Nicotine)，又名尼古丁，是一种存在于茄科植物中的生物碱。烟碱具有旋光性，有(R)-烟碱和(S)-烟碱两种对映异构体。天然产物以(S)-烟碱为主，(R)-烟碱是较少丰富的对映异构体，其含量通常不超过10％。由于共同的理化性质(R)-烟碱的药理作用在性质上与(S)-烟碱的药理作用相似，两者的给药途径的效率基本相同且穿越生物屏障的难易程度也是相同的。(R)-烟碱与(S)-烟碱具有本质相似的药理学作用，只是在作用时间上稍慢于(S)-烟碱，但其毒性远远低于(S)-烟碱。目前，市场上所用的烟碱主要为(S)-烟碱，大多从烟草中提取得到。但由于受到烟草原材料生长、产量、气候等因素的影响，含量较低，成本较高，难以工业化生产，所以合成烟碱越来越受到人们的重视。
近年来，烟碱对中枢神经系统(CNS)疾病的潜在药理作用已引起大量有机合成和药物化学等领域学者的关注，尤其是烟碱可能对帕金森病(PD)、阿尔茨海默病(AD)、精神分裂症和抑郁症的治疗具有有益作用。此外，烟碱在某些疾病的治疗和功能调节方面具有多种药理作用，如增强人类相关的听觉处理、增加认知功能和刺激交感肾上腺素能系统和具有治疗结节病的潜力。烟碱是一种具有较强生长抑制活性和良好药代动力学特性的抗生素化合物。
现有技术对烟碱进行修饰的报道较多，而关于烟碱2位或6位酰胺型化合物进行的减肥药物的研究尚未见报道。
发明内容
本发明的目的是提供一类新的烟碱酰胺型化合物，并为该类化合物提供一种新用途。
针对上述目的，本发明所采用的烟碱酰胺型化合物的结构式为：
其中，R代表芳香酰基和脂肪酰基，具体可以选自乙酰基、氯乙酰基、硬脂酰基、软脂酰基、正庚酰基、正辛酰基、苯丙酰基、烟酰基、戊炔酰基、氰基乙酰基、三氟甲磺酸酰基、苯甲酰基、对氯苯甲酰基、间氯苯甲酰基、邻氯苯甲酰基、对溴苯甲酰基、对氟苯甲酰基、邻二氟苯甲酰基、对甲基苯甲酰基、对乙基苯甲酰基、间二氯苯甲酰基、对甲苯磺酰基等中任意一种。
本发明烟碱酰胺型化合物优选下述化合物1-30中任意一种：
本发明烟碱酰胺型化合物的合成路线和具体合成方法如下：
1、合成烟碱酰胺型化合物1-17
以干燥的二氯甲烷为溶剂，将化合物A或B与羧酸类化合物ROH、二环己基碳二亚胺(DCC)、4-二甲氨基吡啶(DMAP)按摩尔比为1:1.1～3.5:1.1～2.5:0.1～0.6，室温搅拌反应12～24h。反应完毕后，减压浓缩除去溶剂，浓缩物经硅胶柱层析，得到化合物1-17。
2、合成烟碱酰胺型化合物18-30
以干燥的二氯甲烷为溶剂，将化合物A或B与酰氯RCl、三乙胺按摩尔比为1:1.1～2.5:1.1～3.5，室温搅拌反应4～6h。反应完毕后，萃取，过滤，减压蒸除溶剂，浓缩物经硅胶柱层析，得到化合物18-30。
本发明烟碱酰胺型化合物在制备减肥药物中的用途，其按常规药用制剂，与药学上可接受的载体按照各种制剂的常规制备工艺制成，可以是片剂、颗粒剂、胶囊剂。
本发明的有益效果如下：
本发明以烟碱为母体，将其2位或6位引入氨基后连接不同的羧基制备烟碱酰胺型化合物。经药理活性检测，此类化合物对脂肪酶显示出很好的抑制活性，可以用于制备减肥药物。
具体实施方式
下面结合实施例对本发明进一步详细说明，但本发明的保护范围不仅限于这些实施例。
实施例1
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、软脂酸(144mg，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝32:1)，得到白色固体化合物1(83.9mg，产率为71％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝15:1)。化合物1的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.34–11.18(m,1H),8.37(d,J＝5.0Hz,1H),7.43(d,J＝7.4Hz,1H),6.96–6.92(m,1H),4.53–4.44(m,1H),3.44(s,1H),3.29(t,J＝8.3Hz,1H),3.18(d,J＝8.9Hz,1H),2.49(t,J＝7.8Hz,2H),2.33(t,J＝8.0Hz,2H),2.22(s,2H),1.96–1.90(m,5H),1.72–1.61(m,5H),1.25(s,17H),0.89(d,J＝6.2Hz,4H)ppm；13C NMR(101MHz,CDCl3)δ177.98,157.19,147.24,138.30,123.77,118.61,71.18,56.39,49.25,40.08,34.22,33.86,31.95,31.58,29.72,29.55,29.48,29.40,29.33,29.19,25.63,25.59,24.94,22.72,22.67,14.17ppm；HRMS(ESI)m/z:[M+H]+C26H46N3O理论值416.3635,实测值416.3621。
实施例2
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、3-苯丙酸(85mg，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝27:1)，得到白色固体化合物2(76mg，产率为87％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝13:1)。化合物2的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.21(s,1H),8.35(d,J＝4.9Hz,1H),7.44(d,J＝7.5Hz,1H),7.29(d,J＝7.6Hz,2H),7.24–7.19(m,3H),6.97–6.93(m,1H),3.42(dd,J＝9.6,5.2Hz,1H),3.25(dd,J＝10.1,5.0Hz,1H),2.84(s,2H),2.65(t,J＝8.0Hz,2H),2.31–2.26(m,1H),2.17(s,3H),1.92(d,J＝8.7Hz,1H),1.85–1.81(m,2H),1.70(d,J＝5.2Hz,1H)ppm；13C NMR(101MHz,CDCl3)δ177.65,157.44,150.20,147.08,141.04,138.38,128.49,128.34,126.09,124.06,118.88,111.34,70.92,56.32,40.01,33.79,25.58,24.91,22.63ppm；HRMS(ESI)m/z:[M+H]+C19H24N3O理论值310.1914,实测值310.1900。
实施例3
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、硬脂酸(160mg，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝32:1)，得到白色固体化合物3(104mg，产率为83％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝15:1)。化合物3的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.26(s,1H),8.37(d,J＝4.9Hz,1H),7.42(d,J＝7.4Hz,1H),6.93(d,J＝2.3Hz,1H),4.44(s,1H),3.44(d,J＝11.0Hz,1H),3.29(s,1H),3.17(s,1H),2.48(d,J＝7.8Hz,2H),2.32(t,J＝7.5Hz,2H),2.22(s,2H),2.00–1.92(m,5H),1.73–1.66(m,5H),1.25(s,21H),0.88(s,4H)ppm；13C NMR(101MHz,CDCl3)δ178.26,157.12,147.25,138.28,123.70,118.57,71.21,56.39,49.20,40.08,34.68,33.88,31.95,31.57,30.92,29.72,29.66,29.54,29.48,29.39,29.27,25.63,25.60,25.13,24.95,22.72,22.67,14.17ppm；HRMS(ESI)m/z:[M+H]+C28H50N3O理论值444.3948,实测值444.3934。
实施例4
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、正辛酸(0.1mL，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝30:1)，得到白色固体化合物4(60mg，产率为70％)，TLC:Rf＝0.5(CH2Cl2:CH3OH＝12:1)。化合物4的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.21(s,1H),8.37(d,J＝4.9Hz,1H),7.44(d,J＝7.5Hz,1H),6.94(dd,J＝7.5,5.0Hz,1H),4.63–4.55(m,1H),3.43(s,1H),3.30(t,J＝8.3Hz,1H),3.18(t,J＝8.0Hz,1H),2.50(t,J＝7.7Hz,2H),2.33(s,3H),2.22(s,2H),1.94–1.92(m,3H),1.69(t,J＝4.1Hz,3H),1.31(s,4H),0.88(s,4H)ppm；13C NMR(101MHz,CDCl3)δ178.37,157.33,147.17,138.31,123.95,118.68,71.09,56.38,49.30,40.05,33.81,31.67,29.10,28.94,25.58,24.90,22.61,14.07ppm；HRMS(ESI)m/z:[M+H]+C18H30N3O理论值304.2383,实测值304.2371。
实施例5
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、正庚酸(0.08mL，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝30:1)，得到白色固体化合物5(64mg，产率为78％)，TLC:Rf＝0.5(CH2Cl2:CH3OH＝12:1)。化合物5的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.24(s,1H),8.37(d,J＝4.9Hz,1H),7.43(d,J＝7.4Hz,1H),6.94(d,J＝2.4Hz,1H),3.45(d,J＝4.0Hz,1H),3.29(s,1H),3.15(s,1H),2.33(s,2H),2.22(s,2H),1.93(d,J＝3.1Hz,3H),1.68(t,J＝4.0Hz,4H),1.30(s,5H),0.88(s,4H)ppm；13C NMR(101MHz,CDCl3)δ178.55,157.23,147.20,138.30,123.82,118.64,71.15,56.38,49.24,40.06,33.85,31.54,28.92,25.59,24.92,22.52,14.05ppm；HRMS(ESI)m/z:[M+H]+C17H28N3O理论值290.2227,实测值290.2151。
实施例6
称取化合物A(50mg，0.28mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、4-戊炔酸(56mg，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝26:1)，得到白色固体化合物6(65mg，产率为89％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝12:1)。化合物6的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.27(s,1H),8.34(d,J＝4.9Hz,1H),7.47(d,J＝7.4Hz,1H),6.97(dd,J＝5.2,3.1Hz,1H),3.42(d,J＝4.7Hz,1H),3.33(d,J＝8.5Hz,1H),3.22(t,J＝8.3Hz,1H),2.59–2.56(m,2H),2.52(dd,J＝5.7,3.6Hz,2H),2.35(d,J＝8.9Hz,1H),2.23(s,3H),1.94(s,2H),1.72–1.69(m,2H)ppm；13C NMR(101MHz,CDCl3)δ157.43,150.08,147.03,138.44,124.06,118.99,82.96,70.92,68.78,56.35,49.33,40.06,33.77,24.89,14.47ppm；HRMS(ESI)m/z:[M+H]+C15H20N3O理论值258.1601,实测值258.1590。
实施例7
称取化合物A(70mg，0.395mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(122mg，0.59mmol)、DMAP(24mg，0.198mmol)、2-吡啶甲酸(97mg，0.79mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝28:1)，得到淡黄色固体化合物7(78mg，产率为70％)，TLC:Rf＝0.5(CH2Cl2:CH3OH＝14:1)。化合物7的结构表征数据为：1H NMR(400MHz,CDCl3)δ13.27(s,1H),8.61(d,J＝4.7Hz,1H),8.49(dd,J＝4.7,2.2Hz,1H),8.34(d,J＝7.8Hz,1H),7.87(t,J＝7.7Hz,1H),7.50(d,J＝7.5Hz,1H),7.46–7.42(m,1H),6.99(dd,J＝7.4,5.1Hz,1H),3.48(s,1H),3.28(t,J＝8.5Hz,1H),2.40(t,J＝8.8Hz,1H),2.28(d,J＝1.7Hz,3H),2.11–1.94(m,3H),1.85–1.78(m,1H)ppm；13CNMR(101MHz,CDCl3)δ162.25,156.85,151.23,150.52,148.02,147.40,138.06,137.24,126.10,123.13,118.92,70.63,56.58,40.01,31.95,22.81ppm；HRMS(ESI)m/z:[M+H]+C16H19N4O理论值283.1553,实测值283.1536。
实施例8
称取化合物A(119mg，0.67mmol)溶解在4mL干燥的二氯甲烷中，向溶液中依次加入DCC(207mg，1.01mmol)、DMAP(41mg，0.335mmol)、乙酸(0.1mL，1.34mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝25:1)，得到白色固体化合物8(119mg，产率为81％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝10:1)。化合物8的结构表征数据为：1H NMR(400MHz,CDCl3)δ11.19(s,1H),8.33(d,J＝4.9Hz,1H),7.44(dd,J＝7.5,1.7Hz,1H),6.95(ddd,J＝6.4,5.0,1.3Hz,1H),3.34–3.29(m,1H),3.18(t,J＝8.5Hz,1H),2.33(d,J＝7.3Hz,4H),2.22(d,J＝1.3Hz,3H),2.17–1.96(m,4H)ppm；13C NMR(101MHz,CDCl3)δ150.32,146.99,138.36,123.95,118.72,111.62,71.07,56.41,40.08,31.67,24.99,22.73ppm；HRMS(ESI)m/z:[M+H]+C12H18N3O理论值220.1444,实测值220.1435。
实施例9
称取化合物B(67mg，0.38mmol)溶解在2mL干燥的二氯甲烷中，向溶液中依次加入DCC(117mg，0.57mmol)、DMAP(23mg，0.19mmol)、乙酸(0.05mL，0.76mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝14:1)，得到黄色油状化合物9(43mg，产率为51％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝8:1)。化合物9的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.65(s,1H),8.20(d,J＝2.6Hz,2H),7.78(d,J＝8.7Hz,1H),3.32(t,J＝9.3Hz,1H),3.18(d,J＝21.8Hz,1H),2.42–2.34(m,1H),2.21(s,6H),1.93–1.36(m,4H)ppm；13C NMR(101MHz,CDCl3)δ168.78,146.81,138.05,130.93,128.85,114.13,68.72,56.77,40.04,34.66,24.66,22.34ppm；HRMS(ESI)m/z:[M+H]+C12H18N3O理论值220.1444,实测值220.1432。
实施例10
称取化合物B(119mg，0.67mmol)溶解在4mL的二氯甲烷中，向溶液中依次加入DCC(207mg，1.01mmol)、DMAP(41mg，0.335mmol)、软脂酸(344mg，1.34mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝22:1)，得到白色固体化合物10(162mg，产率为58％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝10:1)。化合物10的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.13(s,1H),8.25(d,J＝8.6Hz,1H),8.13(d,J＝2.2Hz,1H),7.75(d,J＝8.7Hz,1H),3.27(t,J＝8.8Hz,1H),3.07(t,J＝8.3Hz,1H),2.43–2.33(m,4H),2.17(s,3H),1.70(dt,J＝15.4,7.5Hz,4H),1.25(s,24H),0.88(s,4H)ppm；13CNMR(101MHz,CDCl3)δ178.53,172.32,150.91,145.98,138.35,114.34,68.56,56.83,40.19,37.62,34.87,34.49,31.94,29.72,29.68,29.65,29.50,29.39,29.35,29.25,29.22,25.42,25.05,22.72,22.42,14.15ppm；HRMS(ESI)m/z:[M+H]+C26H46N3O理论值416.3635,实测值416.3621。
实施例11
称取化合物B(67mg，0.38mmol)溶解在2mL的二氯甲烷中，向溶液中依次加入DCC(117mg，0.57mmol)、DMAP(23mg，0.19mmol)、3-苯丙酸(113mg，0.76mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝16:1)，得到白色固体化合物11(48mg，产率为41％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝8:1)。化合物11的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.48(s,1H),8.21–8.14(m,2H),7.71(dd,J＝8.6,2.3Hz,1H),7.27(d,J＝7.1Hz,2H),7.21(d,J＝7.1Hz,3H),3.26–3.21(m,1H),3.07–3.01(m,3H),2.69(t,J＝7.8Hz,2H),2.29(q,J＝9.0Hz,1H),2.14(s,3H),1.97–1.69(m,4H)ppm；13C NMR(101MHz,CDCl3)δ170.69,150.64,146.95,140.50,137.69,134.70,128.61,128.32,126.35,114.14,68.56,56.95,40.31,39.33,35.09,31.27,22.49ppm；HRMS(ESI)m/z:[M+H]+理论值C19H24N3O 310.1914,实测值310.1904。
实施例12
称取化合物B(190mg，1.07mmol)溶解在6mL的二氯甲烷中，向溶液中依次加入DCC(331mg，1.60mmol)、DMAP(65mg，0.53mmol)、硬脂酸(608mg，2.14mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝22:1)，得到白色固体化合物12(292mg，产率为61％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝10:1)。化合物12的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.25(s,1H),8.26(d,J＝8.6Hz,1H),8.13(d,J＝2.3Hz,1H),7.76(dd,J＝8.7,2.3Hz,1H),3.27(t,J＝8.7Hz,1H),3.08(t,J＝8.5Hz,1H),2.38(dt,J＝25.6,7.5Hz,4H),2.17(s,3H),1.69(dq,J＝15.0,7.4Hz,5H),1.25(s,27H),0.88(t,J＝6.6Hz,4H)ppm；13C NMR(101MHz,CDCl3)δ172.37,156.96,150.96,145.94,138.38,114.39,68.55,56.81,49.23,40.17,37.60,34.85,33.92,31.94,29.72,29.68,29.54,29.51,29.39,29.27,29.22,25.61,25.42,25.11,24.94,22.71,22.42,14.14ppm；HRMS(ESI)m/z:[M+H]+理论值C28H50N3O 444.3948,实测值444.3932。
实施例13
称取化合物B(51mg，0.28mmol)溶解在2mL的二氯甲烷中，向溶液中依次加入DCC(87mg，0.42mmol)、DMAP(17mg，0.14mmol)、正辛酸(0.1mL，0.56mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝18:1)，得到淡黄色固体化合物13(75mg，产率为85％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝8:1)。化合物13的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.62(s,1H),8.28(d,J＝8.6Hz,1H),8.11(d,J＝2.3Hz,1H),7.76(dd,J＝8.9,2.3Hz,1H),3.26(t,J＝8.6Hz,1H),3.07(t,J＝8.3Hz,1H),2.42(t,J＝7.5Hz,2H),2.33(q,J＝9.5,8.5Hz,3H),2.16(s,3H),1.69(dd,J＝15.1,7.3Hz,5H),1.30–1.28(m,6H),0.90–0.87(m,4H)ppm；13C NMR(101MHz,CDCl3)δ172.58,151.01,145.60,138.58,134.03,114.53,68.50,56.79,40.18,37.51,34.83,33.89,31.70,29.23,29.03,25.42,22.65,14.11ppm；HRMS(ESI)m/z:[M+H]+理论值C18H30N3O 304.2383,实测值304.2371。
实施例14
称取化合物B(96mg，0.54mmol)溶解在3mL的二氯甲烷中，向溶液中依次加入DCC(167mg，0.81mmol)、DMAP(33mg，0.27mmol)、正庚酸(0.15mL，1.08mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝18:1)，得到淡黄色固体化合物14(104mg，产率为67％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝8:1)。化合物14的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.47–8.36(m,1H),8.22–8.17(m,2H),7.74(d,J＝9.0Hz,1H),4.28(dt,J＝18.7,7.3Hz,1H),3.28(t,J＝8.8Hz,1H),3.09(t,J＝8.4Hz,1H),2.38(t,J＝7.5Hz,2H),2.18(s,3H),1.85–1.67(m,6H),1.30(dq,J＝7.2,4.5,3.2Hz,6H),0.90–0.86(m,3H)ppm；13C NMR(101MHz,CDCl3)δ171.80,156.79,147.11,137.79,128.85,113.98,65.59,56.82,49.15,37.82,33.97,31.54,28.89,25.63,24.96,22.50,14.04ppm；HRMS(ESI)m/z:[M+H]+理论值C17H28N3O 290.2227,实测值290.2209。
实施例15
称取化合物B(100mg，0.56mmol)溶解在3mL的二氯甲烷中，向溶液中依次加入DCC(173mg，0.84mmol)、DMAP(34mg，0.28mmol)、氰乙酸(95mg，1.12mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝14:1)，得到淡黄色固体化合物15(92mg，产率为68％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝7:1)。化合物15的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.69–9.10(m,1H),8.25(s,1H),8.10(d,J＝8.6Hz,1H),7.78(d,J＝8.7Hz,1H),3.65(s,1H),3.28(t,J＝8.8Hz,1H),3.14(t,J＝8.3Hz,1H),2.20(d,J＝8.8Hz,3H),1.96–1.84(m,2H),1.26(s,2H),0.92–0.83(m,2H)ppm；13C NMR(101MHz,CDCl3)δ159.85,149.82,147.08,138.17,135.59,114.59,113.94,68.50,56.88,40.25,34.98,29.71,22.51ppm；HRMS(ESI)m/z:[M+H]+理论值C13H17N4O 245.1397,实测值245.1382。
实施例16
称取化合物B(100mg，0.56mmol)溶解在3mL的二氯甲烷中，向溶液中依次加入DCC(173mg，0.84mmol)、DMAP(34mg，0.28mmol)、4-戊炔酸(110.6mg，1.12mmol)，在室温下反应24h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝15:1)，得到棕色油状化合物16(114mg，产率为79％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝8:1)。化合物16的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.59(s,1H),8.27(d,J＝8.6Hz,1H),8.14(t,J＝2.1Hz,1H),7.80–7.77(m,1H),3.30(t,J＝8.8Hz,1H),3.13(t,J＝8.3Hz,1H),2.69–2.65(m,2H),2.61–2.58(m,2H),2.55(d,J＝6.7Hz,1H),2.35(d,J＝9.0Hz,1H),2.18(d,J＝1.7Hz,3H),1.95–1.84(m,2H),1.74–1.58(m,2H)ppm；13C NMR(101MHz,CDCl3)δ169.83,156.75,147.04,138.16,114.30,106.67,82.65,69.48,68.76,56.64,40.02,36.14,34.34,22.23,14.48ppm；HRMS(ESI)m/z:[M+H]+理论值C15H20N3O 258.1601,实测值258.1588。
实施例17
称取化合物B(140mg，0.79mmol)溶解在5mL的二氯甲烷中，向溶液中依次加入DCC(244mg，1.18mmol)、DMAP(48mg，0.395mmol)、2-吡啶甲酸(195mg，1.58mmol)，在室温下反应12h后减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝20:1)，得到黄色固体化合物17(150mg，产率为67％)，TLC:Rf＝0.5(CH2Cl2:CH3OH＝10:1)。化合物17的结构表征数据为：1H NMR(400MHz,CDCl3)δ10.55(s,1H),8.64(d,J＝4.8Hz,1H),8.39(dd,J＝8.5,2.0Hz,1H),8.31–8.27(m,2H),7.91(t,J＝7.7Hz,1H),7.78(d,J＝8.6Hz,1H),7.49(t,J＝6.3Hz,1H),3.26(t,J＝8.7Hz,1H),3.08(t,J＝8.2Hz,1H),2.30(t,J＝8.9Hz,1H),2.19(d,J＝2.1Hz,3H),1.80(td,J＝15.9,13.7,7.5Hz,2H),1.32(dd,J＝18.8,7.7Hz,2H)ppm；13C NMR(101MHz,MeOD)δ162.75,158.46,150.41,148.90,148.46,147.41,137.84,133.79,127.08,122.08,113.69,68.51,56.45,39.09,33.37,24.67ppm；HRMS(ESI)m/z:[M+H]+理论值C16H19N4O 283.1553,实测值283.1539。
实施例18
称取化合物A(100mg，0.56mmol)溶解在3mL的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加4-氯苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL的二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:2)，得到黄色固体化合物18(132.1mg，产率为52％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝1:1)。化合物18的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.37(d,J＝4.6Hz,1H),8.10(d,J＝7.9Hz,1H),7.73(dd,J＝11.7,8.0Hz,4H),7.32(dd,J＝14.0,8.8Hz,5H),3.30(t,J＝8.3Hz,1H),3.21(t,J＝8.6Hz,1H),2.27(d,J＝9.1Hz,1H),2.12(s,3H),1.98–1.50(m,4H)ppm；13C NMR(101MHz,CDCl3)δ172.24,172.08,151.52,148.15,139.01,138.10,137.45,132.93,132.79,130.69,128.95,128.85,124.64,65.38,56.65,40.40,34.21,22.91ppm；HRMS(ESI)m/z:[M+H]+理论值C24H22Cl2N3O2454.1084,实测值454.1070。
实施例19
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加2,6-二氟苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:1.5)，得到淡黄色固体化合物19(147.3mg，产率为57％)，TLC:Rf＝0.5(乙酸乙酯:石油醚＝1.5:1)。化合物19的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.41(dd,J＝4.4,2.2Hz,1H),8.17–8.11(m,1H),7.34–7.21(m,3H),6.80(dt,J＝27.0,8.6Hz,4H),3.49(t,J＝8.2Hz,1H),3.22(t,J＝8.4Hz,1H),2.35(d,J＝9.0Hz,1H),2.16(s,3H),1.94–1.57(m,4H)ppm；13C NMR(101MHz,CDCl3)δ162.89,162.87,160.50,157.97,149.04,147.95,138.62,137.68,132.72,132.62,132.51,125.14,111.82,111.70,111.66,111.61,111.57,111.49,111.45,64.41,56.85,40.20,34.66,23.06ppm；HRMS(ESI)m/z:[M+H]+C24H20F4N3O2理论值458.1486,实测值458.1384。
实施例20
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加间氯苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL的二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:3)，得到黄色固体化合物20(168.5mg，产率为66％)，TLC:Rf＝0.4(乙酸乙酯:石油醚＝1:2)。化合物20的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.41–8.36(m,1H),8.15(dd,J＝7.9,1.7Hz,1H),7.74(d,J＝16.4Hz,2H),7.66(t,J＝8.3Hz,2H),7.43(t,J＝9.1Hz,2H),7.32(ddt,J＝15.8,7.6,4.1Hz,3H),3.35(s,1H),3.28(s,1H),2.35–2.31(m,1H),2.18(s,3H),2.01–1.62(m,4H)ppm；13C NMR(101MHz,CDCl3)δ171.91,151.28,148.24,138.20,136.84,136.22,136.08,134.81,132.61,130.01,129.86,129.56,129.31,129.14,128.00,127.30,127.18,124.77,65.59,56.59,40.43,34.14,22.83ppm；HRMS(ESI)m/z:[M+H]+C24H22Cl2N3O2理论值454.1084,实测值454.1042。
实施例21
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加邻氯苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:1)，得到黄色油化合物21(156mg，产率为61％)，TLC:Rf＝0.4(乙酸乙酯:石油醚＝1.5:1)。化合物21的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.53(dd,J＝4.5,2.0Hz,1H),8.35(dd,J＝7.7,1.8Hz,1H),7.71–7.65(m,2H),7.41(d,J＝3.0Hz,1H),7.21(d,J＝4.4Hz,6H),3.80(t,J＝8.4Hz,1H),3.60–3.55(m,1H),2.51(q,J＝9.0Hz,1H),2.36(d,J＝1.4Hz,3H),2.16–1.88(m,4H)ppm；13C NMR(101MHz,CDCl3)δ169.30,150.64,148.87,138.04,135.61,134.83,132.10,131.83,130.50,130.40,130.33,129.63,126.69,126.57,126.47,125.15,65.73,56.49,39.92,33.90,22.46ppm；HRMS(ESI)m/z:[M+H]+C24H22Cl2N3O2理论值454.1084,实测值454.1032。
实施例22
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，加入4-溴苯甲酰氯(134mg，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:2.5)，得到淡黄色固体化合物22(160.7mg，产率为53％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝1:1)。化合物22的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.37(d,J＝4.7Hz,1H),8.10(d,J＝7.8Hz,1H),7.65(dd,J＝12.2,8.1Hz,4H),7.49(dd,J＝14.6,8.1Hz,4H),7.31(dd,J＝7.8,4.7Hz,1H),3.29(t,J＝8.2Hz,1H),3.21(t,J＝8.5Hz,1H),2.27(d,J＝9.0Hz,1H),2.12(s,3H),1.95–1.55(m,4H)ppm；13C NMR(101MHz,CDCl3)δ172.38,172.23,151.45,148.14,138.12,137.44,133.35,133.21,131.94,131.84,131.51,131.45,130.78,127.65,124.65,65.38,56.65,40.42,34.21,22.92ppm；HRMS(ESI)m/z:[M+H]+C24H22Br2N3O2理论值542.0073,实测值542.0032。
实施例23
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加对氟苯甲酰氯(0.07mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:1.5)，得到淡黄色固体化合物23(141.2mg，产率为60％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝1:1)。化合物23的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.42–8.38(m,1H),8.13–8.10(m,1H),7.83–7.79(m,3H),7.32(dd,J＝7.9,4.7Hz,1H),7.14–6.97(m,5H),3.34(t,J＝8.3Hz,1H),3.24(t,J＝8.5Hz,1H),2.32–2.26(m,1H),2.13(s,3H),1.94–1.59(m,4H)ppm；13C NMR(101MHz,CDCl3)δ172.12,171.98,166.43,163.90,151.79,148.19,138.09,137.32,132.53,132.44,131.98,131.89,124.60,115.95,115.86,115.72,115.64,115.50,115.29,65.40,56.63,40.34,34.16,22.85ppm；HRMS(ESI)m/z:[M+H]+C24H22F2N3O2理论值422.1675,实测值422.1627。
实施例24
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加对甲基苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:3)，得到淡黄色固体化合物24(178.9mg，产率为77％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝1:2)。化合物24的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.36(d,J＝4.6Hz,1H),8.08(d,J＝7.8Hz,1H),7.70(dd,J＝10.7,8.0Hz,4H),7.23(d,J＝7.5Hz,1H),7.12(dd,J＝14.6,7.8Hz,4H),3.38(t,J＝8.3Hz,1H),3.21(t,J＝8.5Hz,1H),2.85(s,1H),2.33(d,J＝6.2Hz,6H),2.15(d,J＝2.0Hz,3H),1.94–1.55(m,4H)ppm；13C NMR(101MHz,CDCl3)δ173.44,173.25,152.34,147.94,143.17,137.75,137.32,132.07,131.94,129.97,129.56,129.51,129.19,129.08,128.97,124.15,65.29,56.71,40.44,34.19,22.92,21.66,21.61ppm；HRMS(ESI)m/z:[M+H]+C26H28N3O2理论值414.2176,实测值414.2134。
实施例25
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加对乙基苯甲酰氯(0.09mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:2.5)，得到淡黄色固体化合物25(192.1mg，产率为78％)，TLC:Rf＝0.4(乙酸乙酯:石油醚＝1:1)。化合物25的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.35(dd,J＝4.7,2.3Hz,1H),8.06(d,J＝7.8Hz,1H),7.71(dd,J＝14.6,7.8Hz,4H),7.26(t,J＝2.3Hz,1H),7.13(dd,J＝16.9,7.8Hz,4H),3.36(t,J＝8.2Hz,1H),3.17(t,J＝8.5Hz,1H),2.62(p,J＝7.7Hz,4H),2.26(t,J＝9.0Hz,1H),2.14(d,J＝1.7Hz,3H),1.93–1.70(m,4H),1.19(q,J＝7.4Hz,6H)ppm；13C NMR(101MHz,CDCl3)δ173.52,173.23,152.37,149.25,149.21,147.88,137.66,137.59,132.32,132.24,129.67,129.58,127.97,127.85,124.09,65.23,56.78,40.50,34.28,28.86,23.01,15.07ppm；HRMS(ESI)m/z:[M+H]+C28H32N3O2理论值442.2489,实测值442.2441。
实施例26
称取化合物A(90mg，0.508mmol)溶解在3mL的二氯甲烷中，加入三乙胺(0.12mL，0.76mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加苯甲酰氯(0.07mL，0.558mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL的二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:1.5)，得到黄色油状物26(108.3mg，产率为55％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝1:1)。化合物26的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.39(d,J＝4.6Hz,1H),8.12–8.08(m,1H),7.79(t,J＝8.8Hz,4H),7.43(d,J＝8.9Hz,2H),7.36–7.28(m,5H),3.41(t,J＝8.3Hz,1H),3.25(t,J＝8.6Hz,1H),2.27(t,J＝9.0Hz,1H),2.17(s,3H),1.96–1.57(m,4H)ppm；13C NMR(101MHz,CDCl3)δ173.45,173.27,152.07,148.10,137.85,137.19,134.91,134.79,132.74,132.42,129.95,129.38,129.34,128.50,128.40,128.28,124.37,65.42,56.68,40.39,34.17,22.87ppm；HRMS(ESI)m/z:[M+H]+理论值C24H24N3O2 386.1863,实测值386.1855。
实施例27
称取化合物A(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加3,5-二氯苯甲酰氯(0.09mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL的二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝1:6)，得到白色固体化合物27(143.1mg，产率为49％)，TLC:Rf＝0.4(乙酸乙酯:石油醚＝1:4)。化合物27的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.39(dd,J＝4.4,2.0Hz,1H),8.17(d,J＝7.8Hz,1H),7.61(d,J＝13.3Hz,4H),7.46(d,J＝11.5Hz,2H),7.36(dd,J＝8.1,4.7Hz,1H),3.31(dt,J＝16.8,8.5Hz,2H),2.38(d,J＝9.8Hz,1H),2.19(s,3H),2.09–1.64(m,4H)ppm；13C NMR(101MHz,CDCl3)δ170.51,150.63,148.42,138.52,136.47,135.55,134.93,132.52,128.28,127.32,125.10,124.86,65.69,56.51,40.44,34.12,22.83ppm；HRMS(ESI)m/z:[M+H]+C24H20Cl4N3O2理论值522.0304,实测值522.0262。
实施例28
称取化合物B(53mg，0.3mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，加入对甲苯磺酰氯(69mg，0.36mmol)，然后将反应混合物在室温下搅拌4h。向其中加入1mol/L的盐酸水溶液除去吡啶，再用5mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝13:1)，得到白色固体化合物28(61mg，产率为42％)，TLC:Rf＝0.3(CH2Cl2:CH3OH＝7:1)。化合物28的结构表征数据为：1HNMR(400MHz,CDCl3)δ8.21(d,J＝5.8Hz,5H),6.51(d,J＝5.9Hz,6H),3.02(s,12H),1.92(dd,J＝12.7,4.1Hz,1H),1.68(d,J＝12.0Hz,1H),1.26(s,2H)ppm；13C NMR(101MHz,CDCl3)δ154.53,148.73,148.67,130.93,128.84,106.58,65.58,49.00,39.14,33.96,29.71,25.65,24.97ppm；HRMS(ESI)m/z:[M+H]+理论值C24H28N3O4S2 486.1516,实测值486.1494。
实施例29
称取化合物B(79mg，0.44mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.1mL，0.675mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加氯乙酰氯(0.04mL，0.49mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为乙酸乙酯:石油醚＝2:1)，得到棕色油状化合物29(143.1mg，产率为44％)，TLC:Rf＝0.3(乙酸乙酯:石油醚＝4:1)。化合物29的结构表征数据为：1H NMR(400MHz,CDCl3)δ9.21(d,J＝44.9Hz,1H),8.24(d,J＝8.4Hz,1H),7.82(dt,J＝7.6,3.5Hz,1H),4.93(ddd,J＝35.9,8.9,5.5Hz,1H),4.22(s,2H),4.07(d,J＝3.5Hz,2H),3.59(dt,J＝14.0,7.2Hz,1H),3.40–3.33(m,1H),3.07(d,J＝1.2Hz,2H),2.95(s,1H),2.08–1.67(m,4H)ppm；13C NMR(101MHz,CDCl3)δ166.76,164.73,150.20,145.89,137.68,134.28,114.10,59.60,46.80,42.83,41.35,36.58,35.48,24.30ppm；HRMS(ESI)m/z:[M+H]+C14H18Cl2N3O2理论值330.0771,实测值330.0753。
实施例30
称取化合物B(100mg，0.56mmol)溶解在3mL干燥的二氯甲烷中，加入三乙胺(0.12mL，0.84mmol)，室温下搅拌5min，然后在冰浴中冷却反应溶液，滴加邻氯苯甲酰氯(0.08mL，0.61mmol)，在室温下反应4h后加入5mL水淬灭反应，再用10mL二氯甲烷萃取3次，合并二氯甲烷相，无水硫酸钠干燥，过滤，减压浓缩除去溶剂，得到的浓缩物通过硅胶柱分离(洗脱剂为CH2Cl2:CH3OH＝30:1)，得到黄色油状化合物30(127mg，产率为50％)，TLC:Rf＝0.4(CH2Cl2:CH3OH＝18:1)。化合物30的结构表征数据为：1H NMR(400MHz,CDCl3)δ8.39(s,1H),8.07(d,J＝8.2Hz,1H),7.77(d,J＝7.5Hz,1H),7.52(dd,J＝10.8,8.2Hz,3H),7.40(d,J＝7.7Hz,1H),7.34–7.27(m,2H),7.22–7.19(m,2H),3.61(t,J＝8.9Hz,1H),3.50(t,J＝8.5Hz,1H),2.61(q,J＝9.1Hz,1H),2.27(s,3H),2.26–1.92(m,4H)ppm；13C NMR(101MHz,CDCl3)δ169.15,151.80,149.36,137.98,135.10,132.50,131.50,131.40,130.95,130.73,130.50,130.02,129.54,126.64,126.48,123.39,68.56,56.01,39.01,33.28,21.96ppm；HRMS(ESI)m/z:[M+H]+C24H22Cl2N3O2理论值454.1084,实测值454.1015。
实施例31
本发明烟碱酰胺型化合物在制备减肥药物中的应用
分别将上述化合物1～30作为受试化合物，测试其对脂肪酶的抑制活性，具体试验情况如下：
将三油酸(80mg)、磷脂酰胆碱(10mg)和牛磺胆酸(5mg)悬浮在含有0.1M氯化钠的9mL0.1MN-三(羟甲基)甲基-2-氨基-乙烯磺酸(TES)缓冲液(pH7.0)中，超声处理5分钟。将超声处理的基质悬浮液(100μL)与50μL(10个单位)的胰脂肪酶和100μL各种样品溶液一起在37℃培养30分钟，最终体积为250μL，测定释放的油酸量。将培养混合物添加到含有2％(v/v)MeOH的1:1(v/v)CHCl3和正庚烷混合物的3mL等分试样中，并通过在振动筛中水平摇动试管10min进行提取。将混合物在2000g下离心10分钟，并通过抽吸去除上层水相。然后将铜试剂(1mL)添加到较低的有机相中。将混合物以2000g离心10min，并用0.5mL0.1％(w/v)巴妥卡因在含有0.05％(w/v)3(2)-叔丁基-4-羟基茴香醚的氯仿中处理0.5mL上层有机相(其中含有提取的游离脂肪酸的铜盐)。然后在480nm处测量吸光度。
试验结果见表1。
表1化合物1～30对胰脂肪酶的抑制活性
从表1的胰脂肪酶抑制活性数据可知，本发明的烟碱酰胺型化合物对胰脂肪酶表现出了很好的抑制活性，效果明显优于烟碱，可用于制备减肥药物。
Claims (2)
1.烟碱酰胺型化合物，其特征在于该化合物为下述中任意一种：
2.权利要求1所述的烟碱酰胺型化合物在制备减肥药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513052.3A CN115611855B (zh) | 2022-05-11 | 2022-05-11 | 烟碱酰胺型化合物及其在制备减肥药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513052.3A CN115611855B (zh) | 2022-05-11 | 2022-05-11 | 烟碱酰胺型化合物及其在制备减肥药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115611855A CN115611855A (zh) | 2023-01-17 |
| CN115611855B true CN115611855B (zh) | 2023-11-24 |
Family
ID=84856450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210513052.3A Active CN115611855B (zh) | 2022-05-11 | 2022-05-11 | 烟碱酰胺型化合物及其在制备减肥药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115611855B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101203500A (zh) * | 2005-01-25 | 2008-06-18 | Epix特拉华公司 | 取代的芳胺化合物和它们作为5－ht6调节剂的用途 |
| CN101318943A (zh) * | 2007-06-05 | 2008-12-10 | 中国科学院上海药物研究所 | 一类取代哌嗪类化合物、其制备方法、用途及包含此类化合物的药物组合物 |
| CN109422728A (zh) * | 2017-08-27 | 2019-03-05 | 中南民族大学 | 一类氮杂环丁烷衍生物及其合成方法 |
-
2022
- 2022-05-11 CN CN202210513052.3A patent/CN115611855B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101203500A (zh) * | 2005-01-25 | 2008-06-18 | Epix特拉华公司 | 取代的芳胺化合物和它们作为5－ht6调节剂的用途 |
| CN101318943A (zh) * | 2007-06-05 | 2008-12-10 | 中国科学院上海药物研究所 | 一类取代哌嗪类化合物、其制备方法、用途及包含此类化合物的药物组合物 |
| CN109422728A (zh) * | 2017-08-27 | 2019-03-05 | 中南民族大学 | 一类氮杂环丁烷衍生物及其合成方法 |
Non-Patent Citations (2)
| Title |
|---|
| CAS号：224569-47-5、205864-15-9;STN Registry;STN Registry;第1-2页 * |
| Conjugate of Bovine Serum Albumin With Nicotine;Hajime Matsushita 等;BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS;第57卷;第1007页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115611855A (zh) | 2023-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113336705B (zh) | 一种大麻二酚-2-咪唑-1-甲酸酯及其应用 | |
| CN115611855B (zh) | 烟碱酰胺型化合物及其在制备减肥药物中的应用 | |
| CN107216283B (zh) | 一种含有二氢吡啶结构的β-榄香烯衍生物及其制备方法和用途 | |
| CN113956266A (zh) | 一种规模化合成河豚毒素的方法 | |
| CN107365265B (zh) | 夹竹桃麻素水溶性前药、其制备方法、药物组合物及用途 | |
| CN105985401B (zh) | 一种雷公藤红素衍生物、其制备方法及用途 | |
| CN113072553B (zh) | 脱氢蟾蜍色胺的制备方法和用途 | |
| CN114057710A (zh) | 一种具有抗肿瘤活性的水飞蓟宾化学修饰物及其制备方法 | |
| CZ2000711A3 (cs) | Opticky čisté analogy kamptothecinu, meziprodukty syntézy a způsob přípravy | |
| CN114341362A (zh) | 一种(r)-1,2,3,4-四氢异喹啉-1-羧酸及其衍生物和左旋吡喹酮的制备方法 | |
| CN106928224B (zh) | 吲哚类槐定碱衍生物及其制备方法 | |
| CN1310920C (zh) | 消旋和光活胡桐素a及其类似物的制备方法 | |
| CN110759961A (zh) | 一类熊果酸吲哚醌酰胺衍生物及其制备方法和应用 | |
| JP2004083570A (ja) | 低酸素応答誘導剤およびその製法 | |
| CN109206389A (zh) | 异土木香内酯衍生物，其药物组合物及其用途 | |
| CN112824426B (zh) | 一种别孕烯醇酮膦酰胺衍生物、其制备方法及其在医药上的用途 | |
| CN107722017A (zh) | 一种阿那格雷衍生物的制备方法 | |
| CN109517026B (zh) | L-苯丙氨酸修饰的山楂酸及其合成方法和应用 | |
| CN109422742B (zh) | 9位取代的娃儿藤碱衍生物及其制备和在抗烟草花叶病毒活性中的应用 | |
| KR100365649B1 (ko) | 항암제로서의 데커신의 유도체 및 그 합성방법 | |
| CN107602612B (zh) | 喹啉酮磷酸酯衍生物及其合成方法和应用 | |
| JPH02122000A (ja) | エライオフイリンおよびエライオフイリン誘導体の塩基性開裂生成物 | |
| CN114478566A (zh) | 消除冬凌草甲素1位羟基的衍生物及用途 | |
| CN116474110A (zh) | 近红外二区长循环前药偶联物，其制备方法及与sting受体激动剂的联合应用 | |
| CN116284039A (zh) | 青蒿琥酯手性杂质的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |